Foundation Medicine

Foundation Medicine may be growing as indicated by several key developments. The company has consolidated its employees into a new headquarters in Seaport, which suggests an expansion of its operations and possibly an increase in its workforce. Additionally, Foundation Medicine has been mentioned as a leading player in the cancer therapy and testing market, which is experiencing a boom, alongside other key players. This market recognition is a qualitative indicator of the company's prominence and potential growth in the industry. Furthermore, the company's involvement in the development of companion diagnostics, which have received FDA approval, points to successful product development and regulatory milestones that are critical for growth in the biotechnology and medical sectors.

Foundation Medicine is advancing personalized cancer therapies through methods for predicting treatment response to mono-immunotherapy and determining tumor mutational burden (TMB) using sequence read data. They are also developing systems for identifying HLA variants and methods for multigene analysis of tumor samples. Their research includes detecting BRAF gene fusions and using tumor heterogeneity scores as prognostic biomarkers. These efforts focus on enhancing diagnostic precision and tailoring cancer treatments.